Department of Neurosurgery, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Department of Radiation Oncology, REM Radioterapia srl, 95029 Viagrande, Italy.
Curr Oncol. 2022 Jul 9;29(7):4842-4855. doi: 10.3390/curroncol29070384.
Craniovertebral junction (CVJ) schwannomas are rare, with surgery and stereotactic radiosurgery (SRS) being effective yet challenging options. We systematically reviewed the literature on CVJ schwannomas.
PubMed, Scopus, Web-of-Science, and Cochrane were searched following the PRISMA statement to include studies reporting CVJ schwannomas. Clinical features, management, and outcomes were analyzed.
We collected 353 patients from 101 included articles. Presenting symptoms were mostly neck pain (30.3%) and headache (26.3%), with most cranial neuropathies involving the XII (31.2%) and X (24.4%) nerves. Most tumors originated from C2 (30.9%) and XII (29.4%) nerves, being extracranial (45.1%) and intradural-extradural (44.2%). Erosion of C1-C2 vertebrae (37.1%), the hypoglossal canal (28.3%), and/or jugular foramen (20.1%) were noted. All tumors were operated, preferably with the retrosigmoid approach (36.5%), with the far-lateral approach (29.7%) or with the posterior approach and cervical laminectomy (26.9%), far-lateral approaches (14.2%), or suboccipital craniotomy with concurrent cervical laminectomy (14.2%). Complete tumor resection was obtained most frequently (61.5%). Adjuvant post-surgery stereotactic radiosurgery was delivered in 5.9% patients. Median follow-up was 27 months (range, 12-252). Symptom improvement was noted in 88.1% of cases, and cranial neuropathies showed improvement in 10.2%. Post-surgical complications occurred in 83 patients (23.5%), mostly dysphagia (7.4%), new cranial neuropathies (6.2%), and cerebrospinal fluid leak (5.9%). A total of 16 patients (4.5%) had tumor recurrence and 7 died (2%), with median overall survival of 2.7 months (range, 0.1-252).
Microsurgical resection is safe and effective for CVJ schwannomas. Data on SRS efficacy and indications are still lacking, and its role deserves further evaluation.
颅颈交界区(CVJ)神经鞘瘤罕见,手术和立体定向放射外科(SRS)是有效的治疗方法,但具有挑战性。我们系统地回顾了有关 CVJ 神经鞘瘤的文献。
根据 PRISMA 声明,在 PubMed、Scopus、Web-of-Science 和 Cochrane 中进行了检索,以纳入报道 CVJ 神经鞘瘤的研究。分析了临床特征、治疗方法和结局。
我们从 101 篇纳入的文章中收集了 353 名患者。主要的首发症状是颈部疼痛(30.3%)和头痛(26.3%),大多数颅神经病变涉及 XII(31.2%)和 X(24.4%)神经。大多数肿瘤起源于 C2(30.9%)和 XII(29.4%)神经,为颅外(45.1%)和硬脊膜外(44.2%)。注意到 C1-C2 椎体侵蚀(37.1%)、舌下神经管(28.3%)和/或颈静脉孔(20.1%)。所有肿瘤均行手术治疗,首选乙状窦后入路(36.5%),远外侧入路(29.7%)或后路和颈椎椎板切除术(26.9%)、远外侧入路(14.2%)或枕下开颅术联合同期颈椎椎板切除术(14.2%)。最常获得完全肿瘤切除(61.5%)。术后辅助行立体定向放射外科治疗的患者占 5.9%。中位随访时间为 27 个月(范围,12-252)。88.1%的病例症状改善,10.2%的颅神经病变改善。83 例患者(23.5%)出现术后并发症,主要为吞咽困难(7.4%)、新的颅神经病变(6.2%)和脑脊液漏(5.9%)。16 例患者(4.5%)肿瘤复发,7 例死亡(2%),总体中位生存时间为 2.7 个月(范围,0.1-252)。
显微外科切除是治疗 CVJ 神经鞘瘤的安全有效方法。关于 SRS 疗效和适应证的数据仍然缺乏,其作用值得进一步评估。